Minocycline in phenotypic models of Huntington's disease
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Minocycline has been shown to be neuroprotective in various models of neurodegenerative diseases. However, its potential in Huntington's disease (HD) models characterized by calpain-dependent degeneration and inflammation has not been investigated. Here, we have tested minocycline in phenotypic models of HD using 3-nitropropionic acid (3NP) intoxication and quinolinic acid (QA) injections. In the 3NP rat model, where the development of striatal lesions involves calpain, we found that minocycline was not protective, although it attenuated the development of inflammation induced after the onset of striatal degeneration. The lack of minocycline activity on calpain-dependent cell death was also confirmed in vitro using primary striatal cells. Conversely, we found that minocycline reduced lesions and inflammation induced by QA. In cultured cells, minocycline protected against mutated huntingtin and staurosporine, stimulations known to promote caspase-dependent cell death. Altogether, these data suggested that, in HD, minocycline may counteract the development of caspase-dependent neurodegeneration, inflammation, but not calpain-dependent neuronal death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183 · cited 1×
“…spinal cord injury, ischemia) (Brundula et al., 2002; Kriz et al., 2002; Lee et al., 2003; Stirling et al., 2004; Tomas-Camardiel et al., 2004; Wu et al., 2002; Yrjanheikki et al., 1999; see also Blum et al., 2004, for review), although recent studies pointed out that it may also be…”
BackgroundEarly mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines
Panov, A. V., Gutekunst, C.-A., Leavitt, B. R., Hayden, M. R., Burke, J. R., Strittmatter, W. J., & Greenamyre, J. T. (2002) · Nature Neuroscience · doi:10.1038/nn884 · Cited by 1,030 · cited 2×
“, 2003) and promotes mitochondrial complex II dysfunction (Beal, 2000), mitochondrial Ca defects (Panov et al., 2002), NMDA receptor sensitization (Song et al.”
BackgroundTetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
Yrjänheikki, J., Keinänen, R., Pellikka, M., Hökfelt, T., & Koistinaho, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15769 · Cited by 1,006 · cited 1×
“Previous observations reported that high doses of both minocycline and doxycycline provided protection against cerebral ischemia (Yrjanheikki et al., 1998).”
BackgroundHuntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes
Zuccato, C., Tartari, M., Crotti, A., Goffredo, D., Valenza, M., Conti, L., Cataudella, T., Leavitt, B. R., Hayden, M. R., Timmusk, T., et al. (2003) · Nature Genetics · doi:10.1038/ng1219 · Cited by 979 · cited 2×
“The mutation involved produces a polyglutamine expansion within the Nterminal part of the huntingtin protein (The Huntington’s Disease Collaborative Research Group, 1993), which leads to many neuronal alterations such as impairments in transcription (Cha, 2000; Zuccato et al., 2003), calcium signaling (Tang et al.”
BackgroundNonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease
Turmaine, M., Raza, A., Mahal, A., Mangiarini, L., Bates, G. P., & Davies, S. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.110078997 · Cited by 430 · cited 2×
“injections of minocycline improve motor alterations in the R6/2 transgenic mouse model of HD—that is characterized by very limited neuronal loss even at very late stages (Turmaine et al., 2000)—Smith et al.”
BackgroundResultTomás-Camardiel, M., Rite, I., Herrera, A. J., de Pablos, R. M., Cano, J., Machado, A., & Venero, J. L. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.01.010 · Cited by 203 · cited 3×
“However, our results are in accordance with the known anti-inflammatory activity of minocycline found in other models of degenerative diseases and suggested in the R6/2 HD model (Amin et al., 1996; Chen et al., 2000; Dommergues et al., 2003; He et al., 2001; Kriz et al., 2002; Tikka and Koistinaho, 2001; Tomas-Camardi…”
BackgroundResultDeleterious Effects of Minocycline in Animal Models of Parkinson’s Disease and Huntington’s Disease
Diguet, E., Fernagut, P., Wei, X., Du, Y., Rouland, R., Gross, C., Bezard, E., & Tison, F. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03372.x · Cited by 189
Minocycline Enhances MPTP Toxicity to Dopaminergic Neurons
Yang, L., Sugama, S., Chirichigno, J. W., Gregorio, J., Lorenzl, S., Shin, D. H., Browne, S. E., Shimizu, Y., Joh, T. H., Beal, M. F., et al. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10709 · Cited by 158 · cited 4×
“…et al., 2004; Wu et al., 2002; Yrjanheikki et al., 1999; see also Blum et al., 2004, for review), although recent studies pointed out that it may also be detrimental (Diguet et al., 2004a; Tsuji et al., 2004; Yang et al., 2003; see also for review Blum et al., 2004; Diguet et al., 2004b).”
BackgroundResultInfluentialClinical Potential of Minocycline for Neurodegenerative Disorders
BLUM, D., CHTARTO, A., TENENBAUM, L., BROTCHI, J., & LEVIVIER, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.012 · Cited by 157 · cited 4×
“…et al., 2004; Wu et al., 2002; Yrjanheikki et al., 1999; see also Blum et al., 2004, for review), although recent studies pointed out that it may also be detrimental (Diguet et al., 2004a; Tsuji et al., 2004; Yang et al., 2003; see also for review Blum et al., 2004; Diguet et al., 2004b).”
BackgroundSelf-citation
Cited by
Spires, T. L., Orne, J. D., SantaCruz, K., Pitstick, R., Carlson, G. A., Ashe, K. H., & Hyman, B. T. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050840 · Cited by 401
Brouillet, E., Jacquard, C., Bizat, N., & Blum, D. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03515.x · Cited by 364
Self-citationBioactive lipids, inflammation and chronic diseases
Leuti, A., Fazio, D., Fava, M., Piccoli, A., Oddi, S., & Maccarrone, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.028 · Cited by 358
Boudreau, R. L., McBride, J. L., Martins, I., Shen, S., Xing, Y., Carter, B. J., & Davidson, B. L. (2009) · Molecular Therapy · doi:10.1038/mt.2009.17 · Cited by 339
McBride, J. L., Pitzer, M. R., Boudreau, R. L., Dufour, B., Hobbs, T., Ojeda, S. R., & Davidson, B. L. (2011) · Molecular Therapy · doi:10.1038/mt.2011.219 · Cited by 247
Metadata
- Authors
- Bantubungi, K., Jacquard, C., Greco, A., Pintor, A., Chtarto, A., Tai, K., Galas, M.-C., Tenenbaum, L., Déglon, N., Popoli, P., Minghetti, L., Brouillet, E., Brotchi, J., Levivier, M., Schiffmann, S. N., & Blum, D.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2005-02
- Volume
- 18
- Issue
- 1
- Pages
- 206-217
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W1980636359
- Cited by
- 52
- References
- 9
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.